Mark C. Mc Kenna Prometheus Biosciences, Inc. (RXDX) insider trading activity

Mark C. Mc Kenna is Chairman, President and CEO of Prometheus Biosciences, Inc.. Currently has a direct ownership of 0 shares of RXDX, which is worth approximately $0. The most recent transaction as insider was on Jun 16, 2023, when has been sold 178,098 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Mark C. McKenna Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 16 2023	SELL Sale (or disposition) back to the issuer	-	178,098 Reduced 100.0%	0 Common Stock
Jun 02 2023	BUY Exercise of conversion of derivative security	$281,821 $2.3 p/Share	122,531 Added 40.77%	178,036 Common Stock
Mar 15 2023	SELL Open market or private sale	$2,903,500 $116.14 p/Share	25,000 Reduced 31.19%	55,144 Common Stock
Mar 15 2023	BUY Exercise of conversion of derivative security	$72,500 $2.9 p/Share	25,000 Added 23.78%	80,144 Common Stock
Mar 03 2023	SELL Open market or private sale	$1,328,880 $125.13 p/Share	10,620 Reduced 16.15%	55,144 Common Stock
Mar 03 2023	BUY Exercise of conversion of derivative security	$39,294 $3.7 p/Share	10,620 Added 13.9%	65,764 Common Stock
Mar 01 2023	SELL Open market or private sale	$87,682 $125.26 p/Share	700 Reduced 1.25%	55,144 Common Stock
Mar 01 2023	BUY Exercise of conversion of derivative security	$2,590 $3.7 p/Share	700 Added 1.24%	55,844 Common Stock
Feb 17 2023	SELL Open market or private sale	$1,711,368 $125.1 p/Share	13,680 Reduced 19.88%	55,144 Common Stock
Feb 17 2023	BUY Exercise of conversion of derivative security	$50,616 $3.7 p/Share	13,680 Added 16.58%	68,824 Common Stock
Feb 16 2023	SELL Open market or private sale	$2,996,750 $119.87 p/Share	25,000 Reduced 31.19%	55,144 Common Stock
Feb 16 2023	BUY Exercise of conversion of derivative security	$92,500 $3.7 p/Share	25,000 Added 23.78%	80,144 Common Stock
Feb 15 2023	SELL Open market or private sale	$2,985,500 $119.42 p/Share	25,000 Reduced 31.19%	55,144 Common Stock
Feb 15 2023	BUY Exercise of conversion of derivative security	$72,500 $2.9 p/Share	25,000 Added 23.78%	80,144 Common Stock
Jan 17 2023	SELL Open market or private sale	$2,974,750 $118.99 p/Share	25,000 Reduced 31.19%	55,144 Common Stock
Jan 17 2023	BUY Exercise of conversion of derivative security	$72,500 $2.9 p/Share	25,000 Added 23.78%	80,144 Common Stock
Dec 09 2022	BUY Grant, award, or other acquisition	-	37,113 Added 40.23%	55,144 Common Stock
Dec 01 2021	BUY Exercise of conversion of derivative security	$44,660 $2.9 p/Share	15,400 Added 50.0%	15,400 Common Stock

Also insider at

APGE

Apogee Therapeutics, Inc.

Director

AGLE

Aeglea BioTherapeutics, Inc. Healthcare

NAMS

NewAmsterdam Pharma Co N.V.

MCM

Mark C. Mc Kenna

Chairman, President and CEO

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXDX shares.

Notify only if

Value

Insider Trading

Get notified when an Prometheus Biosciences, Inc. insider buys or sells RXDX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Prometheus Biosciences, Inc.

Track Activities on RXDX

Account